Trends in prescribing preferences (PPrefs) of US-based oncologists for patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) following docetaxel (DO).

被引：0
|
作者：
Ryan, Charles J.
Kim, Won
Buettner, Arden
Britton, Susan Lynne
Lankford, Maria L.
Neely, Doug B.
Green, Mark R.
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Xcenda, Tampa, FL USA
[4] Xcenda, Palm Harbor, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
243
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease
    Schmidt, Andrew Lachlan
    Anton, Angelyn
    Wong, Shirley S.
    Azad, Arun
    Kwan, Edmond Michael
    Spain, Lavinia Anne
    Torres, Javier
    Muthusamy, Arunbalaji
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey C.
    Joshua, Anthony M.
    Pook, David William
    Gibbs, Peter
    Tran, Ben
    Weickhardt, Andrew James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Prospective evaluation of prescribing preferences (PPrefs) of US-based oncologists in the postdocetaitel mCRPC patient (Pt)
    Ryan, Charles J.
    Buettner, Arden
    Britton, Susan L.
    Lankford, Maria
    Neely, Doug B.
    Green, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment
    Gernone, A.
    Pagliarulo, A.
    Calderoni, G.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [4] Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
    Thomson, Alastair
    Pollard, Adam
    Mark, Frances May
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Ning, Yang-Min
    Theoret, Marc Robert
    Arlen, Philip M.
    Parnes, Howard L.
    Ojemuyiwa, Michelle A.
    Strauss, Julius
    Dawson, Nancy Ann
    McLeod, David G.
    Harold, Nancy
    Couvillon, Anna
    Cordes, Lisa M.
    Chen, Clara
    Steinberg, Seth M.
    Sissung, Tristan M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [7] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [8] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Molina, A. M.
    Christos, P. J.
    Whang, Y.
    Nordquist, L.
    Hackett, A. L.
    Beltran, H.
    Faltas, B.
    Nanus, D.
    Giannakakou, P.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Massard, Christophe
    Retz, Margitta
    Tafreshi, Ali
    Carles Galceran, Joan
    Hammerer, Peter
    Fong, Peter C. C.
    Shore, Neal D.
    Joshua, Anthony
    Linch, Mark David
    Gurney, Howard
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] Evolution of docetaxel-based therapy for metastatic castrate-resistant prostate cancer
    Cornford, Philip
    JOURNAL OF CLINICAL UROLOGY, 2010, 3 (06) : 225 - 230
12345